Local Application of Timolol 0.5% Solution in Treating Chronic Non-Healing Ulcers – A Prospective Study
DOI:
https://doi.org/10.18196/jfaps.v4i1.19143Keywords:
Beta-Adrenergic Receptor antagonist, Chronic Non-Healing Ulcer, Mechanical debridementAbstract
Chronic non-healing ulcers are a variety of ulcers that occur mainly over the lower limb and are resistant to conventional therapy. There are modern treatments like various types of dressings and topical preparations available in the market. However, they are costly and may not be freely available to the general population. Topical usage of β2-AR antagonists like timolol may promote wound healing by enabling keratinocyte migration into the wound to initiate the re-epithelisation. The objective of this study is to assess the effectiveness of topical timolol 0.5% in accelerating the wound healing process by observing the signs of healing. It is a prospective observational study conducted in Government General Hospital, Rangaya Medical Medical College, Kakinada, after getting Institutional Ethical Committee approval from March 2021 to March 2023. One hundred patients with Chronic non-healing foot ulcers were taken for this study. Mean age was 47.64.60% of the study population was in the 20-55 years age group. Reduction in mean ulcer area was on day 15 and day 30 with topical application of timolol.References
Frykberg RG, Banks J. Challenges in the treatment of chronic wounds. Adv Wound Care (New Rochelle). 2015;4(9):560–82. http://dx.doi.org/10.1089/wound.2015.0635
Agale SV. Chronic leg ulcers: Epidemiology, aetiopathogenesis, and management. Ulcers. 2013;2013:1–9. http://dx.doi.org/10.1155/2013/413604
Robertson D, Biaggioni I. Adrenoceptor Antagonist Drugs. In: Katzung BG, Trevor AJ. Basic & Clinical Pharmacology. 13th ed. McGraw-Hill; 2015.
Sivamani RK, Lam ST, Isseroff RR. Beta adrenergic receptors in keratinocytes. Dermatol Clin. 2007;25(4):643–53. http://dx.doi.org/10.1016/j.det.2007.06.012
Pullar CE, Chen J, Isseroff RR. PP2A activation by β2-adrenergic receptor agonists. J Biol Chem. 2003;278(25):22555–62 http://dx.doi.org/10.1074/jbc.m300205200
Tang JC, Dosal J, Kirsner RS. Topical timolol for a refractory wound. Dermatol Surg. 2012;38(1):135–8. http://dx.doi.org/10.1111/j.1524-4725.2011.02200.x
Kaur R, Tchanque-Fossuo C, West K, Hadian Y, Gallegos A, Yoon D, et al. Beta-adrenergic antagonist for the healing of chronic diabetic foot ulcers: study protocol for a prospective, randomized, double-blinded, controlled and parallel-group study. Trials. 2020;21(1). http://dx.doi.org/10.1186/s13063-020-04413-z
Braun LR, Lamel SA, Richmond NA, Kirsner RS. Topical timolol for recalcitrant wounds. JAMA Dermatol. 2013;149(12):1400. http://dx.doi.org/10.1001/jamadermatol.2013.7135
Alsaad AMS, Alsaad SM, Fathaddin A, Al-Khenaizan S. Topical timolol for vasculitis ulcer: A potential healing approach. JAAD Case Rep. 2019;5(9):812–4. http://dx.doi.org/10.1016/j.jdcr.2019.07.016
Oliver TI, Mutluoglu M. Diabetic Foot Ulcer. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
Vestita M, Filoni A, Bonamonte D, Annoscia P, Giudice G. Abstract: Topical 0.5% timolol for chronic refractory wounds. An observational prospective study. Plast Reconstr Surg Glob Open. 2017;5(9S):21–21. http://dx.doi.org/10.1097/01.gox.0000526190.20003.08
Manahan MN, Peters P, Scuderi S, Surjana D, Beardmore GL. Topical timolol for a chronic ulcer — a case with its own control. Med J Aust. 2014;200(1):49–50. http://dx.doi.org/10.5694/mja13.10823
Lev-Tov H, Dahle S, Moss J, Isseroff RR. Successful treatment of a chronic venous leg ulcer using a topical beta-blocker. J Am Acad Dermatol. 2013;69(4):e204–5. http://dx.doi.org/10.1016/j.jaad.2013.06.003
Thomas B, Kurien JS, Jose T, Ulahannan SE, Varghese SA. Topical timolol promotes healing of chronic leg ulcer. J Vasc Surg Venous Lymphat Disord. 2017;5(6):844–50. http://dx.doi.org/10.1016/j.jvsv.2017.04.019
Larsen L, Tchanque-Fossuo CN, Gorouhi F, Boudreault D, Nguyen C, Fuentes JJ, et al. Combination therapy of autologous adipose mesenchymal stem cell-enriched, high-density lipoaspirate and topical timolol for healing chronic wounds: Combination Therapy of Autologous Adipose Stem Cell and Timolol for Healing Wound. J Tissue Eng Regen Med. 2018;12(1):186–90. http://dx.doi.org/10.1002/term.2390
Dabiri G, Tiger J, Goreshi R, Fischer A, Iwamoto S. Topical timolol may improve overall scar cosmesis in acute surgical wounds. Cutis. 2017;100(1):E27-E28.
Al Mokadem SM, Ibrahim AM, El Sayed AM. Efficacy of Topical Timolol 0.5% in the Treatment of Acne and Rosacea: A Multicentric Study. J Clin Aesthet Dermatol. 2020;13(3):22–7.
Alcántara-Reifs CM, Salido-Vallejo R, Garnacho-Saucedo GM, Vélez García-Nieto A. Classic Kaposi’s sarcoma treated with topical 0.5% timolol gel: Topical timolol treatment of Kaposi’s sarcoma. Dermatol Ther. 2016;29(5):309–11. http://dx.doi.org/10.1111/dth.12381
Chiaverini C, Passeron T, Lacour JP. Topical timolol for chronic wounds in patients with junctional epidermolysis bullosa. J Am Acad Dermatol. 2016;75(6):e223–4. http://dx.doi.org/10.1016/j.jaad.2016.08.005
Yoon DJ, Kaur R, Gallegos A, West K, Yang H, Schaefer S, et al. Repurposing ophthalmologic timolol for dermatologic use: Caveats and historical review of adverse events. Am J Clin Dermatol. 2021;22(1):89–99. http://dx.doi.org/10.1007/s40257-020-00567-3
Chen L, Tsai TF. The role of β‐blockers in dermatological treatment: a review. J Eur Acad Dermatol Venereol. 2018;32(3):363–71. http://dx.doi.org/10.1111/jdv.14566
Baltazard T, Senet P, Momar D, Picard C, Joachim C, Adas A, et al. Evaluation of timolol maleate gel for management of hard-to-heal chronic venous leg ulcers. Phase II randomised-controlled study. Ann Dermatol Venereol. 2021;148(4):228–32 http://dx.doi.org/10.1016/j.annder.2020.11.009
Cahn B, Kaur R, Hirt P, Tchanque-Fossuo C, Dahle S, Kirsner R, et al. Use of topical timolol maleate as re-epithelialization agent for treatment of recalcitrant wounds of varying etiologies. J Drugs Dermatol. 2020;19(12):1252–6. http://dx.doi.org/10.36849/jdd.2020.5306
